Related Experiment Video
Updated: Jan 10, 2026
06:03
Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
Published on: February 6, 2020
7.0K
Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial
Jeff P Sharman1, Bin Liu1, Denise Y Wang1
1Jeff P. Sharman, MD, Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR; Bin Liu, MSc, MPH, Denise Y. Wang, PhD, and Ching Ching Leow, PhD, Eli Lilly and Company, Indianapolis, IN; and Paul M. Barr, MD, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
Abstract
No abstract available in PubMed .
Related Concept Videos
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:11Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K